Stay ahead of developments in federal and state health care law, regulation and transactions with timely, expert news and analysis.
Congress should change the definition of “medical necessity” to include tests that predict illnesses before they occur, the policy-making body of the American Bar Association said Feb. 6.
The ABA House of Delegates adopted a resolution at the midyear meeting in Miami to change the 50-year-old language of the Social Security Act so that it no longer excludes the predictive genomic testing that is the cornerstone of precision medicine.
The resolution would amend Section 1862(a)(1) of the Social Security Act (42 U.S.C. 1395y) that now says Medicare may not pay for any expenses that aren’t reasonable and necessary for the diagnosis or treatment of illness or to improve the functioning of a malformed part of the body. The ABA resolution would revise the definition, incorporating components such as the concept of testing for future illnesses using genomic medicine and interventions to prevent or mitigate against those illnesses or injuries. The resolution also urges the executive branch of government to adopt similar regulations.
“The importance of the ABA resolution is that it goes on the record,” John E. Steiner Jr., attorney, consultant and former associate general counsel and chief compliance and privacy officer for Cancer Treatment Centers of America, told Bloomberg BNA in a Feb. 6 phone interview. He noted there is a history of attempts to expand the statutory language concerning medical necessity based on various policy reasons. “The reason here is the growth of precision medicine,” Steiner said.
The wording of the resolution is as follows: “That the American Bar Association urges Congress to amend Section 1862(a)(1) of the Social 2 Security Act (42 U.S.C. 1395y) and urges the Executive Branch to adopt regulations that broaden the scope of Medicare coverage by allowing for coverage for items and services that are reasonable and necessary: (a) for the diagnosis, prognosis or treatment of current or future conditions, illnesses, or injuries; or (b) to improve the functioning of a malformed or impaired body member or function; or (c) to mitigate against the future onset or severity of any prognosticated illness, injury or condition, taking into account supporting scientific evidence and evidence-based recommendations supporting their use.”
The resolution further said the American Bar Association urges Congress to define “prognosis” as forecasting the likelihood of or probable course of any current or future illness, injury or condition.
The House of Delegates made additions and no deletions to the resolution as proposed, adding the language on the executive branch adopting similar regulations, the need to take into account scientific evidence and evidence-based recommendations and the definition of prognosis.
The ABA resolution report by the ABA Health Law Section says it is the hope of its authors that the recommended language change in the statute “will also spill over to the commercial market,” noting that a major limiting factor to insurers covering predictive testing is the lack of industry standardization.
While a particular commercial insurer may be willing to invest in genetic testing and mitigating actionable therapies across insured populations to reduce the likelihood of future diseases, it may be reluctant to do so unless its enrolled lives stay with it over the long term, the resolution says.
“This is why a change in Medicare’s definition of medical necessity matters,” the report says. “As the government’s role in healthcare continues to grow, the lines between public payors and private payors have blurred.“More and more private payors base their coverage and reimbursement rates for services on what CMS [Centers for Medicare and Medicaid Services] defines as reimbursable under Medicare. Consequently, if Medicare adopts reimbursement methodologies that pay for prognostic tests and actionable therapies, it is our hope that more commercial insurers will follow.”
To contact the reporter on this story: John T. Aquino in Washington at email@example.com
To contact the editor responsible for this story: Randy Kubetin at RKubetin@bna.com
The adopted resolution is at http://src.bna.com/l0E
Copyright © 2017 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)